Study: Herpes Vaccine in Development Shows Promise; CBCD Reviews a Report

Share Article

A phase 1 vaccine trial produced an immune cell response in 95 per cent of people, according to a report published on news.com.au on October 3, 2014. (1) The CBCD still recommends effective, natural HPV remedies.

News Image
Until an effective vaccine becomes available, the CBCD recommends targeting the latent herpes virus with Novirin or Gene-Eden-VIR. - Greg Bennett, CBCD

“Infected with the herpes virus (HSV-1 or HSV-2)? The CBCD recommends taking Novirin or Gene-Eden-VIR.” - Greg Bennett, CBCD

Dr. Ian Frazer, the scientist behind the HPV vaccine, Gardasil has scored a win with the results of a phase 1 herpes vaccine trial. A phase 1 vaccine trial is a closely monitored study trial of a new vaccine conducted in a small number of healthy volunteers, to determine safety in humans, metabolism, pharmacologic actions, and side effects at various doses. David Rhodes, the science officer of Australian healthcare group, Admedus, said “the primary goal of the new vaccine was not to prevent the spread of herpes simplex but to treat it.” (1) Results of the study showed that the new herpes vaccine “produced a T-cell response in 95 per cent of the humans it was tested in.” (1) T cells are killer immune system cells that detect cells infected with a virus and kill them. Importantly, the report noted that “Over time the trials will be extended to test whether the vaccine also works to prevent the spread of the virus but this type of study takes a long period and must involve lots of people.” (1) The Center for the Biology of Chronic Disease (CBCD) reminds the public that FDA approval of vaccines takes time. Until Dr. Frazier’s new vaccine against HSV passes further testing and gains FDA approval, the CBCD recommends that HSV infected individuals take Novirin or Gene-Eden-VIR. The formula of these natural antiviral supplements was designed to help the immune system target the latent HSV.

Click to learn more about herpes symptoms.

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the herpes simplex virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HSV … reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that, “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Regarding results of the phase 1 vaccine trial, Chief executive officer of Admedus, Lee Rodne, said: “The very encouraging results, clean safety profile and cellular immune responses demonstrated in this HSV-2 study are particularly encouraging and validate the potential of our range of therapeutic vaccines which utilises Professor Frazer’s novel immunotherapy technology.” (See ProactiveInvestors.com.au, from October 2, 2014) (3)

What treatments against genital herpes are currently on the market?

“Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day.” (2)

“Until an effective vaccine becomes available, the CBCD recommends targeting the latent herpes virus with Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was shown to effectively reduce herpes symptoms in two separate post-marketing clinical studies.” - Greg Bennett, CBCD

Click to learn more about Novirin and HSV and Gene-Eden-VIR and HSV.

References:

(1) news.com.au - "Professor Ian Frazer is developing vaccines for herpes simplex and cervical cancer." Published on October 03, 2014.
http://www.news.com.au/lifestyle/health/professor-ian-frazer-is-developing-vaccines-for-herpes-simplex-and-cervical-cancer/story-fneuzlbd-1227078011314

(2) Polansky, H., Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

(3) ProactiveInvestors.com.au - "Admedus vaccine for herpes has success; moves to next clinical trial." Published on October 2, 2014.
http://www.proactiveinvestors.com.au/companies/news/57916/admedus-vaccine-for-herpes-has-success-moves-to-next-clinical-trial-57916.html

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Bennett
CBCD
+1 5852509999
Email >
Visit website